Palisade Bio Collaboration to Advance Precision Medicine for Ulcerative Colitis

Biopharmaceutical company, Palisade Bio, Inc. (Nasdaq: PALI) has entered into a strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, to advance precision medicine for ulcerative colitis (UC) therapy. The company’s share price rose nearly 30% in intraday trading following the news.

The collaboration will provide Palisade Bio with access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors, which are a target for the treatment of inflammation-based diseases.

“Our partnership with Strand Life Sciences signifies a pivotal advancement in our mission to revolutionize UC treatment,” said Dr. Mitch Jones, CMO at Palisade Bio. “By harnessing the power of bioinformatics and leveraging extensive patient datasets, we are highly optimistic in our ability to deliver personalized therapies that offer new hope to patients living with UC. More immediately, the findings from this collaboration will provide valuable guidance and insight for our lead program, PALI-2108.”

Leveraging data from over ten UC clinical studies, Palisade has curated a pipeline of 1600 UC patient samples, including transcriptomics and clinical outcomes. This curated dataset, analyzed using in-house tools, enables Palisade to identify biomarkers for selecting UC patient responders, utilizing machine learning to develop a precision medicine approach to patient selection.

About Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com